Abstract:[Objective] To compare the clinical outcomes of anterior cervical discectomy and fusion (ACDF) with personalized (3Dprinted) zero profile fusion device (the PZPD) versus the finished zero profile fusion device (the FZPD) in the treatment of single-level cer-vical myelopathy. [Methods] A retrospective study was conducted on 46 patients who underwent ACDF for single-level cervical myelopa-thy in our hospital from January 2019 to September 2022. According to doctor-patient communication, 12 patients had ACDF performedwith the PZPD, while other 34 patients were treated with poly-ether-etherke-tone (PEEK) FZPD. The data of the perioperative period, fol-low-up and images were compared between the two groups. [Results] There were no significant differences in operation time, total incisionlength, intraoperative blood loss, fluoroscopy times, ambulation time and hospital stay between the two groups (P>0.05), but the PZPDgroup consumed significantly less device placement time than the FZPD group [(8.6±0.8) min vs (9.4±0.9) min, P=0.007]. The mean followuptime was (34.1±13.2) months, and there was no significant difference in time to return full weight-bearing activity between the twogroups (P>0.05). The NDI and JOA scores, as well as pyramidal tract sign were significantly improved in both groups over time postopera-tively (P<0.05). The PZPD group proved significantly superior to the FZPD group in terms of JOA score [(16.4±0.8) vs (15.9±0.7), P=0.034]6 months postoperativwly, JOA score [(16.7±0.7) vs (16.0±0.8), P=0.008] and NDI score [(0.8±2.0) vs (1.3±1.4), P=0.027] at the latest fol-low-up. Radiographically, the PZPD group had significantly greater intervertebral height than the FZPD group at the last follow-up [(8.4±0.7) mm vs (7.4±0.8) mm, P<0.001], although there were no statistically significant differences in cervical lordosis angle, spinal canal sagit-tal diameter and Bridwell fusion grade between the two groups at any corresponding time points (P>0.05). [Conclusion] The personalizedzero profile fusion device has advantages of quick device placement, better intervertebral height maintenance, more effective relief of preop-erative symptoms, and better early clinical efficacy over the finished counterpart in ACDF for cervical myelopathy.